Compare Quest Diagnostics Inc (DGX) vs First Citizens BancShares Inc (FCNCA) Price & Performance

Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.

The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.

First Citizens BancShares (FCNCA) trades at $2,065.89, down slightly (-0.27%) with a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats (Q2 2026 EPS of $57.09 vs. $40.69 expected) and robust profitability (25.23% net margin). Recent developments include branch expansions and significant commercial lending activity, though cash flow trends show heavy investment outflows. Analyst sentiment is cautious with 82% hold ratings despite a $2,290 consensus price target suggesting modest upside potential.

FCNCA presents a mixed investment case with solid fundamentals offset by technical weakness and cautious analyst sentiment. The stock offers value characteristics with an 11.08 P/E ratio and dividend income, but faces headwinds from bearish technical indicators and institutional selling pressure. Key risks include execution of expansion strategy and potential margin compression in a competitive banking environment.